Mifepristone

Drug GenBioPro, Inc.
Total Payments
$269,065
Transactions
17
Doctors
10
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $49,471 2 2
2023 $108,618 8 8
2022 $39,050 2 2
2021 $36,951 3 3
2020 $34,975 2 2

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $161,947 10 60.2%
Unspecified $107,118 7 39.8%

Payments by Type

General
$161,947
10 transactions
Research
$107,118
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
MERMAID Study GenBioPro, Inc. $107,118 7

Top Doctors Receiving Payments for Mifepristone

Doctor Specialty Location Total Records
, M.D Gynecology Phoenix, AZ $142,947 4
, MD Obstetrics & Gynecology Cleveland, OH $30,800 1
, M.D Obstetrics & Gynecology Charleston, SC $20,977 1
, MD Specialist Washington, DC $17,600 5
, MD FAC OG Obstetrics & Gynecology Gulfport, MS $14,000 1
, M.D Obstetrics & Gynecology Hastings, NE $14,000 1
, M.D Maternal & Fetal Medicine San Diego, CA $9,500 1
, M.D Obstetrics & Gynecology New Bern, NC $9,500 1
, M.D Obstetrics & Gynecology Norfolk, VA $8,341 1
, M.D Obstetrics & Gynecology Lost Angeles, CA $1,400 1

About Mifepristone

Mifepristone is a drug associated with $269,065 in payments to 10 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is GenBioPro, Inc..

Payment data is available from 2020 to 2024. In 2024, $49,471 was paid across 2 transactions to 2 doctors.

The most common payment nature for Mifepristone is "Consulting Fee" ($161,947, 60.2% of total).

Mifepristone is associated with 1 research study, including "MERMAID Study" ($107,118).